Evidence has shown that the absence of CDR1as is directly associated with the heightened metastatic potential of melanoma cells, while cells expressing higher levels of CDR1as demonstrate increased sensitivity to GPX4 inhibitors (181). Here, LINC00632 is linked to melanoma.